Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.67B | $7.80B | $7.93B | $7.98B | $6.13B | $6.83B | $6.94B | $7.39B | $7.68B | $8.23B |
| Revenue growth | — | 1.8% | 1.7% | 0.6% | -23.2% | 11.4% | 1.6% | 6.5% | 3.8% | 7.2% |
| Operating income | $821M | $799M | $33.8M | $1.14B | $83.1M | $860M | $696M | $1.28B | $1.29B | $1.10B |
| Operating margin | 10.7% | 10.2% | 0.4% | 14.3% | 1.4% | 12.6% | 10.0% | 17.3% | 16.7% | 13.3% |
| Net income | $306M | $1.81B | -$379M | $1.13B | -$139M | $402M | $231M | $1.02B | $904M | $705M |
| Net margin | 4.0% | 23.2% | -4.8% | 14.2% | -2.3% | 5.9% | 3.3% | 13.8% | 11.8% | 8.6% |
| EPS (diluted) | $1.51 | $8.90 | -$1.86 | $5.47 | -$0.67 | $1.91 | $1.10 | $4.88 | $4.43 | $3.55 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.63B | $1.58B | $1.75B | $1.59B | $1.20B | $1.50B | $1.36B | $1.58B | $1.50B | $1.70B |
| Capital expenditures | $185M | $156M | $163M | $207M | $112M | $144M | $188M | $291M | $204M | $225M |
| Free cash flow | $1.45B | $1.43B | $1.58B | $1.38B | $1.09B | $1.36B | $1.17B | $1.29B | $1.30B | $1.47B |
| Share buybacks | $416M | — | — | — | — | — | $126M | $692M | $868M | $487M |
| Dividends paid | $188M | $194M | $195M | $197M | $199M | $200M | $201M | $201M | $196M | $190M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $634M | $524M | $543M | $618M | $802M | $378M | $376M | $416M | $526M | $592M |
| Total assets | $26.7B | $26.0B | $24.1B | $24.6B | $24.4B | $23.5B | $21.1B | $21.5B | $21.4B | $23.1B |
| Total liabilities | $17.0B | $14.3B | $12.9B | $12.2B | $12.2B | $10.8B | $9.04B | $9.01B | $8.89B | $10.4B |
| Long-term debt | $10.7B | $8.92B | $8.41B | $6.72B | $7.63B | $5.46B | $5.15B | $4.87B | $5.34B | $6.93B |
| Shareholders' equity | $9.67B | $11.7B | $11.3B | $12.4B | $12.2B | $12.7B | $12.0B | $12.5B | $12.5B | $12.7B |
| Retained earnings | $8.47B | $10.0B | $9.49B | $10.4B | $10.1B | $10.3B | $9.56B | $10.4B | $11.1B | $11.6B |
| Shares (wtd avg diluted) | 202M | 204M | 204M | 207M | 207M | 210M | 210M | 210M | 204M | 199M |
Every figure is extracted from ZIMMER BIOMET HOLDINGS, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.